EGFR基因突变与肺腺癌主要病理分型及标本类型的关系

背景与目的随着基因突变技术及靶向药物治疗如火如荼的开展,对肺腺癌的精准治疗越来越受到关注,目前肺腺癌中研究最多的是表皮生长因子受体(epidermal growth factor receptor,EGFR)。对于EGFR突变和病理分型的关系在不同标本中是否一致,目前不甚明了。本研究比较肺腺癌活检标本和手术切除标本中EGFR基因突变与病理分型的关系是否一致,探讨EGFR基因突变与肺腺癌病理分型的关系以及标本类型对EGFR基因检测的影响。方法收集肺腺癌手术切除标本(楔形肺切除、肺叶切除标本)163例,肺腺癌活检[粘膜活检、肺穿刺、支气管内超声引导针吸活检术(endobronchial ultra...

Full description

Saved in:
Bibliographic Details
Published in:中国肺癌杂志 Vol. 20; no. 6; pp. 382 - 388
Main Author: 康丽菲 郑杰 朱翔
Format: Journal Article
Language:Chinese
Published: 100191 北京,北京大学医学部病理学系 2017
050041 石家庄,河北省胸科医院病理科%北京大学医学部病理学系, 北京,100191
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract 背景与目的随着基因突变技术及靶向药物治疗如火如荼的开展,对肺腺癌的精准治疗越来越受到关注,目前肺腺癌中研究最多的是表皮生长因子受体(epidermal growth factor receptor,EGFR)。对于EGFR突变和病理分型的关系在不同标本中是否一致,目前不甚明了。本研究比较肺腺癌活检标本和手术切除标本中EGFR基因突变与病理分型的关系是否一致,探讨EGFR基因突变与肺腺癌病理分型的关系以及标本类型对EGFR基因检测的影响。方法收集肺腺癌手术切除标本(楔形肺切除、肺叶切除标本)163例,肺腺癌活检[粘膜活检、肺穿刺、支气管内超声引导针吸活检术(endobronchial ultrasound-guided transbronchial needle aspiration,EBUSTBNA)标本]173例,按照2015年世界卫生组织(World Health Organization,WHO)肺腺癌分型标准对其主要组织学分型确认(贴壁型、腺泡型、乳头型、微乳头型、实体型),行EGFR基因检测[基因测序法及突变扩增阻滞系统(amplification refractory mutation system,ARMS)]。分别对活检标本和手术切除标本进行统计。结果163例的肺腺癌手术切除标本中,102例EGFR基因突变,突变率为62.58%,173例的活检标本中,114例EGFR基因突变,突变率为65.9%。两组标本中EGFR突变率没有统计学差异(P〉0.05)。两组标本中女性的EGFR突变率均明显高于男性(P〈0.05)。手术切除标本中60岁以上患者的EGFR突变率明显低于60岁以下(P〈0.05),而活检标本中EGFR突变与年龄无关(P〉0.05)。在EGFR突变的两组标本中病理分型构成比不同(χ2=8.040,P〈0.05)。手术切除标本肺腺癌中EGFR突变的102例中,腺泡型占54.9%(56例),贴壁型占23.53%(24例),乳头型占17.65%(18例),实体型占3.9%(4例),其中腺泡型所占比例最高,其次是贴壁型和乳头型,实体型则比例最少。19、21外显子单独突变最多,21外显子突变在贴壁型较其他两型高(P〈0.05),19外显子突变在乳头型较贴壁型高(P〈0.05)。腺泡型和乳头型比较,19、21外显子突变无统计学意义。活检标本肺腺癌中EGFR突变的114例中腺泡型占48.25%(55例)
AbstractList 背景与目的随着基因突变技术及靶向药物治疗如火如荼的开展,对肺腺癌的精准治疗越来越受到关注,目前肺腺癌中研究最多的是表皮生长因子受体(epidermal growth factor receptor,EGFR)。对于EGFR突变和病理分型的关系在不同标本中是否一致,目前不甚明了。本研究比较肺腺癌活检标本和手术切除标本中EGFR基因突变与病理分型的关系是否一致,探讨EGFR基因突变与肺腺癌病理分型的关系以及标本类型对EGFR基因检测的影响。方法收集肺腺癌手术切除标本(楔形肺切除、肺叶切除标本)163例,肺腺癌活检[粘膜活检、肺穿刺、支气管内超声引导针吸活检术(endobronchial ultrasound-guided transbronchial needle aspiration,EBUSTBNA)标本]173例,按照2015年世界卫生组织(World Health Organization,WHO)肺腺癌分型标准对其主要组织学分型确认(贴壁型、腺泡型、乳头型、微乳头型、实体型),行EGFR基因检测[基因测序法及突变扩增阻滞系统(amplification refractory mutation system,ARMS)]。分别对活检标本和手术切除标本进行统计。结果163例的肺腺癌手术切除标本中,102例EGFR基因突变,突变率为62.58%,173例的活检标本中,114例EGFR基因突变,突变率为65.9%。两组标本中EGFR突变率没有统计学差异(P〉0.05)。两组标本中女性的EGFR突变率均明显高于男性(P〈0.05)。手术切除标本中60岁以上患者的EGFR突变率明显低于60岁以下(P〈0.05),而活检标本中EGFR突变与年龄无关(P〉0.05)。在EGFR突变的两组标本中病理分型构成比不同(χ2=8.040,P〈0.05)。手术切除标本肺腺癌中EGFR突变的102例中,腺泡型占54.9%(56例),贴壁型占23.53%(24例),乳头型占17.65%(18例),实体型占3.9%(4例),其中腺泡型所占比例最高,其次是贴壁型和乳头型,实体型则比例最少。19、21外显子单独突变最多,21外显子突变在贴壁型较其他两型高(P〈0.05),19外显子突变在乳头型较贴壁型高(P〈0.05)。腺泡型和乳头型比较,19、21外显子突变无统计学意义。活检标本肺腺癌中EGFR突变的114例中腺泡型占48.25%(55例)
背景与目的 随着基因突变技术及靶向药物治疗如火如荼的开展,对肺腺癌的精准治疗越来越受到关注,目前肺腺癌中研究最多的是表皮生长因子受体(epidermal growth factor receptor,EGFR).对于EGFR突变和病理分型的关系在不同标本中是否一致,目前不甚明了.本研究比较肺腺癌活检标本和手术切除标本中EGFR基因突变与病理分型的关系是否一致,探讨EGFR基因突变与肺腺癌病理分型的关系以及标本类型对EGFR基因检测的影响.方法 收集肺腺癌手术切除标本(楔形肺切除、肺叶切除标本)163例,肺腺癌活检[粘膜活检、肺穿刺、支气管内超声引导针吸活检术(endobronchial ultrasound-guided transbronchial needle aspiration,EBUS-TBNA)标本]173例,按照2015年世界卫生组织(World Health Organization,WHO)肺腺癌分型标准对其主要组织学分型确认(贴壁型、腺泡型、乳头型、微乳头型、实体型),行EGFR基因检测[基因测序法及突变扩增阻滞系统(amplification refractory mutation system,ARMS)].分别对活检标本和手术切除标本进行统计.结果163例的肺腺癌手术切除标本中,102例EGFR基因突变,突变率为62.58%,173例的活检标本中,114例EGFR基因突变,突变率为65.9%.两组标本中EGFR突变率没有统计学差异(P>0.05).两组标本中女性的EGFR突变率均明显高于男性(P<0.05).手术切除标本中60岁以上患者的EGFR突变率明显低于60岁以下(P<0.05),而活检标本中EGFR突变与年龄无关(P>0.05).在EGFR突变的两组标本中病理分型构成比不同(χ2=8.040,P<0.05).手术切除标本肺腺癌中EGFR突变的102例中,腺泡型占54.9%(56例),贴壁型占23.53%(24例),乳头型占17.65%(18例),实体型占3.9%(4例),其中腺泡型所占比例最高,其次是贴壁型和乳头型,实体型则比例最少.19、21外显子单独突变最多,21外显子突变在贴壁型较其他两型高(P<0.05),19外显子突变在乳头型较贴壁型高(P<0.05).腺泡型和乳头型比较,19、21外显子突变无统计学意义.活检标本肺腺癌中EGFR突变的114例中腺泡型占48.25%(5
Abstract_FL Background and objective With the development of genetic mutations and targeted drugs, ac-curate therapy of lung adenocarcinoma attracts much more attention, and more research is focued on epidermal growth factor receptor (EGFR). It is unclear whether the result of EGFR mutation and pathology type is consistent with differ-ent specimens. In our study, by comparing the relationship between EGFR mutations and pathological classification of lung adenocarcinoma in surgical resection of specimen and biopsy specimen, to discuss the relationship between EGFR mutations and pathological classification of and the influence of specimen type on EGFR gene detection. Methods A total of 163 cases of surgical resection of sample of lung adenocarcinoma (pulmonary resection and pulmonary lobec-tomy) and 173 cases of biopsy specimen [mucosa biopsy, needle biopsy of lung, and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)] were performed by gene sequencing method and amplification refractory mutation system (ARMS) and the majority of the type was confirmed (lepidic, acinar, papillary, micropapil-lary, solid) according to the classification of lung adenocarcinoma in 2015 World Health Organization (WHO). The statistics was used in surgical and biopsy sample respectively. Results The gene mutation of EGFR in surgical and bi-opsy sample of lung adenocarcinoma was 62.58% (102/163) and 65.9% (114/173) respectively, and no significant dif-ference was found (P>0.05). The mutation of EGFR in female was predominant both of the two groups (P<0.05). The mutation rate of EGFR over the age of 60 was significantly lower than that below 60 in surgical specimen, while it was not related to age in biopsy sample. The constituent ratio of pathology type was different in the two groups (χ2=8.04, P<0.05). Among 102 cases of lung adenocarcinoma in surgical specimen, the acinar took up the highest proportion (54.9%), followed by the lepidic (23.53%) and the papillary (17.65%). The solid adenocarcinoma accounted for the minimal percentage (3.9%). The mutation of 19 and 21 exon alone was most common. The mutation rate of 21 exon in the lepidic was higher than that in the acinar and papillary (P<0.05), but the mutation rate of 19 exon in the papil-lary was higher than that in the lepidic (P<0.05). There was no significant difference of 19 and 21 exon in the acinar and papillary. Among 114 cases of lung adenocarcinoma in the biopsy specimen, the most percentage was the acinar (48.25%), the lepidic was secondly, and the papillary, micropapillary and solid adenocarcinoma was the minimal. The exon mutation of 19 and 21 exon alone was most common, while no obvious difference of 19 and 21 exon was found in different pathology classifications (P>0.05). Conclusion The mutation rate of EGFR of lung adenocarcinoma in surgical resected specimen and biopsy specimen was not found difference, which was related to sex, and the female was predominant. The mutation rate of surgical specimen was higher in the young, while that of biopsy specimen was not related to the age. Apparent difference of the pathology type proportion was found in the two groups. The mutation of 19 and 21 exon alone was most common. The mutation of EGFR in surgical specimens was related to pathology types. The percentage of the lepidic adenocarcinoma was highest in the mutation of 21 exon alone. Among the mutation of 19 exon alone, the papillary was predominant. There was no obvious relationship between the mutation of 19 and 21 exon alone and pathology type in biopsy sample.
Author 康丽菲 郑杰 朱翔
AuthorAffiliation 北京大学医学部病理学系,北京100191 河北省胸科医院病理科,石家庄050041
AuthorAffiliation_xml – name: 100191 北京,北京大学医学部病理学系;050041 石家庄,河北省胸科医院病理科%北京大学医学部病理学系, 北京,100191
Author_FL Lifei KANG
Xiang ZHU
Jie ZHENG
Author_FL_xml – sequence: 1
  fullname: Lifei KANG
– sequence: 2
  fullname: Jie ZHENG
– sequence: 3
  fullname: Xiang ZHU
Author_xml – sequence: 1
  fullname: 康丽菲 郑杰 朱翔
BookMark eNo1j09LAkEAxYcwSK0vUYdOu83szO7sHEP8EwhBeJfZnRlTaiyXiLwZaVGR3fpLeeoQXcKL6NdxXD9GG9bpvQc_3uNlQEo3tQRgA0EbU8q2GnY9irSNIGQWJojZDkTUhp4N8RJII8aY5SGfphL_j6yATBQ1IPQchkkaFPLFwp55H5uXQfzZMf3H6ehufj6ed8fx0-10NJl_dOKHbnzfM1c983Zj-tezweXs9Sv-niQxfr4w3WE8nKyCZcUPIrn2p1lQKeQruZJV3i3u5LbLVugybHkESYwFU0QEInACSELORYghoUIhV2LGlFSuwkI6YSAcnzBEuRAi9KUMpY-zYHNRe8q14rpWbTRPWjoZrLZrirfbv_ehByFOyPUFGe43de24nrBHrfohb51VPeq4xKM-xj8q6nY3
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
DBID 2RA
92L
CQIGP
W91
~WA
2B.
4A8
92I
93N
PSX
TCJ
DOI 10.3779/j.issn.1009-3419.2017.06.03
DatabaseName 维普_期刊
中文科技期刊数据库-CALIS站点
中文科技期刊数据库-7.0平台
中文科技期刊数据库-医药卫生
中文科技期刊数据库- 镜像站点
Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Relationship between EGFR Mutations and Pathological Classification and Specimen of Lung Adenocarcinoma
DocumentTitle_FL Relationship between EGFR Mutations and Pathological Classification and Specimen of Lung Adenocarcinoma
EISSN 1999-6187
EndPage 388
ExternalDocumentID zgfazz201706003
672546783
GrantInformation_xml – fundername: 国家自然科学基金项目(No.81300045)资助This study was supported by the grant from the Natural Science Foundation of China (to Xiang ZHU)
  funderid: (81300045)
GroupedDBID ---
-05
04C
29R
2B.
2C~
2RA
2WC
3V.
5GY
5VS
6PF
92F
92I
92L
AAWTL
ABUWG
ACGFS
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVBZV
C1A
CCEZO
CCPQU
CIEJG
CQIGP
CW9
DIK
E3Z
EBD
EIHBH
EMOBN
EOJEC
F5P
GROUPED_DOAJ
HYE
IPNFZ
KQ8
KWQ
OBODZ
OK1
PIMPY
PQQKQ
PROAC
RIG
RNS
RPM
TCJ
TGQ
U1G
U5O
W91
~WA
4A8
93N
PGMZT
PSX
ID FETCH-LOGICAL-c593-641e33d9f4dbdb2b04caadc3047df15e399fef5f3de2cbd284917adddc8eece83
ISSN 1009-3419
IngestDate Wed Nov 06 04:22:55 EST 2024
Wed Feb 14 10:01:01 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Surgical removal specimen
活检标本
手术切除标本
Biopsy specimen
Lung adenocarcinoma
EGFR
肺腺癌
Language Chinese
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c593-641e33d9f4dbdb2b04caadc3047df15e399fef5f3de2cbd284917adddc8eece83
Notes Lifei KANG1,2, Jie ZHENG1, Xiang ZHU1 ( 1Department of Pathology, Peking University, Beijingi00191, China; 2 Department of Pathology, Hebet Chest Hospital, Shijiazhuang 050041, China)
Background and objective With the development of genetic mutations and targeted drugs, accurate therapy of lung adenocarcinoma attracts much more attention, and more research is focued on epidermal growthfactor receptor(EGFR). It is unclear whether the result of EGFR mutation and pathology type is consistent with different specimens. In our study, by comparing the relationship between EGFR mutations and pathological classification of lung adenocarcinoma in surgical resection of specimen and biopsy specimen, to discuss the relationship between EGFR mutations and pathological classification of and the influence of specimen type on EGFR gene detection. Methods A total of 163 cases of surgical resection of sample of lung adenocarcinoma(pulmonary resection and pulmonary lobectomy) and 173 cases of biopsy specimen [mucosa biopsy, needl
PageCount 7
ParticipantIDs wanfang_journals_zgfazz201706003
chongqing_primary_672546783
PublicationCentury 2000
PublicationDate 2017
PublicationDateYYYYMMDD 2017-01-01
PublicationDate_xml – year: 2017
  text: 2017
PublicationDecade 2010
PublicationTitle 中国肺癌杂志
PublicationTitleAlternate Chinese Journal of Lung Cancer
PublicationTitle_FL Chinese Journal of Lung Cancer
PublicationYear 2017
Publisher 100191 北京,北京大学医学部病理学系
050041 石家庄,河北省胸科医院病理科%北京大学医学部病理学系, 北京,100191
Publisher_xml – name: 050041 石家庄,河北省胸科医院病理科%北京大学医学部病理学系, 北京,100191
– name: 100191 北京,北京大学医学部病理学系
SSID ssj0062934
ssib002262905
ssib044765436
ssib001103766
ssib038074678
ssib051369142
Score 2.133899
Snippet 背景与目的随着基因突变技术及靶向药物治疗如火如荼的开展,对肺腺癌的精准治疗越来越受到关注,目前肺腺癌中研究最多的是表皮生长因子受体(epidermal growth factor...
背景与目的 随着基因突变技术及靶向药物治疗如火如荼的开展,对肺腺癌的精准治疗越来越受到关注,目前肺腺癌中研究最多的是表皮生长因子受体(epidermal growth factor...
SourceID wanfang
chongqing
SourceType Aggregation Database
Publisher
StartPage 382
SubjectTerms EGFR
手术切除标本
活检标本
肺腺癌
Title EGFR基因突变与肺腺癌主要病理分型及标本类型的关系
URI http://lib.cqvip.com/qk/91098A/201706/672546783.html
https://d.wanfangdata.com.cn/periodical/zgfazz201706003
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR09b9Uw0GqLVLEgPkUpVJXAEwq8xElsj857eRQhGKAD21M-2-m1ULq8rYgWBIiy8SnoxIBYUJfq9e80TX8Gd46bF1UVHwNLdLmc787n2Hdx7DMh18DFchgQM4vbMrZcP40t4bDEinLR4rmbOlmCE25zD_i9h6ITuuHY-OGqpRHuv7Y04KCtcefsP7R2zRQQAEObwxVaHa5_1e7hre59GnpUdmmgNBBQ1aIhp0pB2IgY0aVS0NClgaAipCFcHU0MgKcBTqWkom1oggAfKV8Xh0ccyRBoUeFrhsIAMqQiMCIE8PFRtOAIyDZVbSwV2JphTQx8QDFXlwLpTNMwoGnGzUYT1TE1CjoNtWttQUoHkUATQB1rF6sRigb8sEJVabCQMyIBFoxK23AJWqMnWvlA1x3Zus2ZkmpLqH6rMc-UtK_rirTRSihMYa2d9jFIwCiXKq6BDpq3oqmMYzBaKSWON7uhaZqrci_4Kwoz6DX9j9Nq9LOmM2HVsUwmLmHV8YdHXR4mjNQuDwXcqAXgokWuM9Oykaev118OFvJoMHCq3EmYK_eEA-M0HgDSuX1nFE3jHtLm173jO3LkHvCoAnCz9fANvR43Ktf0ns18abt1NjcoXC3yONRxklw1Fbj5G_Ux6cniUn_hEYRyemddP4_6C40gcP40OWW-3mZV1e3OkLHB4lkyedesTzlHutj7iq_D4tNW-X2t2Hy_t_Pm4OnwYH1Yfni9t7N78G2tfLdevt0oXmwUX14Vmy_3t57vf_5R_tyF2_Ljs2J9u9zePU_mu-F8e84yJ5VYiSeZ5bt2xlgqYWyL09gBUyRRlCb4RzvNbS-Dj4A8y72cpZmTxClEhNLmEFikiciyJBPsApnoL_Wzi2Q2TlwnFhkTuZdBbC0jIfJIepFMMYqM_CkyXVujt1wlpOn5HE-14IJNkVljn54ZklZ6R9r60p9JpslJhKuJxstk4snj1ewKGV9JV2f0CzKjJ65-AYWPq9o
link.rule.ids 315,782,786,866,4028,27932,27933,27934
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EGFR%E5%9F%BA%E5%9B%A0%E7%AA%81%E5%8F%98%E4%B8%8E%E8%82%BA%E8%85%BA%E7%99%8C%E4%B8%BB%E8%A6%81%E7%97%85%E7%90%86%E5%88%86%E5%9E%8B%E5%8F%8A%E6%A0%87%E6%9C%AC%E7%B1%BB%E5%9E%8B%E7%9A%84%E5%85%B3%E7%B3%BB&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%82%BA%E7%99%8C%E6%9D%82%E5%BF%97&rft.au=%E5%BA%B7%E4%B8%BD%E8%8F%B2&rft.au=%E9%83%91%E6%9D%B0&rft.au=%E6%9C%B1%E7%BF%94&rft.date=2017&rft.pub=100191+%E5%8C%97%E4%BA%AC%2C%E5%8C%97%E4%BA%AC%E5%A4%A7%E5%AD%A6%E5%8C%BB%E5%AD%A6%E9%83%A8%E7%97%85%E7%90%86%E5%AD%A6%E7%B3%BB&rft.issn=1009-3419&rft.volume=20&rft.issue=6&rft.spage=382&rft.epage=388&rft_id=info:doi/10.3779%2Fj.issn.1009-3419.2017.06.03&rft.externalDocID=zgfazz201706003
thumbnail_s http://sdu.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F91098A%2F91098A.jpg
http://sdu.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgfazz%2Fzgfazz.jpg